Eric Lee
6 Papers
6 Citations
Eric Lee is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
FRI0189 Similar efficacy and safety of biosimilar candidate BI 695501 and adalimumab originator reference product in patients with moderate to severe active rheumatoid arthritis: 24 week results from a phase III clinical study (voltaire®-ra)
Stanley Cohen,A Alonso-Ruiz,Piotr Adrian Klimiuk,Eric Lee,Nuala Peter,Ivo Sonderegger,Deepak Assudani +6 more
TL;DR: The co-primary end points of ACR20 response at Wks 12 and 24 were within the pre-defined criteria for equivalence, demonstrating clinical equivalence between BI 695501 and the adalimumab originator (Table 1).
6
Plain language summary of the VOLTAIRE-RA in patients with moderate-to-severe rheumatoid arthritis.
Stanley N. Cohen,Eric Lee +1 more
TL;DR: These results show that both Humira and BI 695501 could be used to treat people with RA as very similar treatment outcomes could be expected.
Poster 261: Increased TT-TG and Tibial Slope are Independent Predictors of ACLR Failure
TL;DR: Increased TT-TG distance, increased lateral tibial slope, and younger age are associated with increased odds of ACL graft failure, and patients may require a more comprehensive strategy to reduce the risk of ACL re-tear.
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
Stanley Cohen,Alberto Alonso-Ruiz,Piotr Adrian Klimiuk,Eric Lee,Nuala Peter,Ivo Sonderegger,Deepak Assudani +6 more
TL;DR: BI 69 5501 demonstrated similar efficacy, safety and immunogenicity to Humira; switch from Humira to BI 695501 had no impact on efficacy,Safety and immunogensicity.
Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext).
TL;DR: Over 2 years, BI 695501 showed similar safety, efficacy, and immunogenicity to adalimumab RP, independent of initial treatment in VOLTAIRE-RA, and no previously unknown ad alimumab side effects were identified.